Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone

Francois Sincholle, Martin Kolb, Helene Manganas, Rabea El Keeb, Marc Newton, Neerav Monga
European Respiratory Journal 2016 48: PA3910; DOI: 10.1183/13993003.congress-2016.PA3910
Francois Sincholle
1Respirology, Hoffmann- La Roche, Mississauga, ONCanada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kolb
2Department of Medicine, Pathology and Molecular Medicine, McMaster University, Hamilton, ONCanada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helene Manganas
3Department of Medicine, Interstitial Lung Disease Clinic, Universite de Montreal, Montreal, QCCanada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rabea El Keeb
4Department of Respiratory Medicine, Lakeridge Health Oshawa. Oshawa Clinic, Oshawa, ONCanada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Newton
5Internal Medicine and Respirology, Grey Bruce Health Services, Owen Sounds, ONCanada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neerav Monga
1Respirology, Hoffmann- La Roche, Mississauga, ONCanada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible and fatal disease. The primary aim of this national multicenter non-interventional study known as the INSPIRATION PLUS registry, is to describe the real world effectiveness and safety of pirfenidone and the clinical management practices in Canada.

Methods: The patients included had a confirmed diagnosis in accordance with the 2011 international guidelines. Data are collected approximately every 3 to 6 months for a minimum of 2 years. The primary objective is to describe and assess the disease course and outcomes in pirfenidone-treated IPF patients in routine clinical practice. The drug utilization patterns will also be described. A validity assessment of the ATAQ-IPF questionnaire will be done compared to three validated but non-specific to IPF Quality of life measures.

Results:

Variablen= 167
Age (year)70.0 ± 8.6
Sex27.5% female 72.5%male
BMIBMI: 29.9 ± 7.1
EthnicityCaucasian: 97.0% Native American: 1.2% Other: 1.8%
Smoking StatusCurrent: 4.8% Former: 69.5%
Exposure to particulates44 (26.3%)
Diagnostic by HRCT only119 /148 (80.4%)
Had a surgical lung biopsy28/145 (18.9%)
Oxygenotherapy19/87 (26.4%)
FVC >80%17 (22.1%)
50-80%47 (61.0%)
<50%13 (16.9%)
mean FVC (%)68.1 ± 17.2
mean DLCO (%)46.3 ± 16.1
mean 6MWD (%)340.4 ± 115.4
On corticosteroids36/87 (50%)

Baseline demographics of the first 167 patients enrolled between 03/2013 and 12/2015

Conclusion: The characteristics of this IPF population at the initiation of pirfenidone indicate that pirfenidone is being used in a wide spectrum of IPF patients in Canada. Follow up data will be presented at a later time.

  • Interstitial lung disease
  • Epidemiology
  • Idiopathic pulmonary fibrosis
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone
Francois Sincholle, Martin Kolb, Helene Manganas, Rabea El Keeb, Marc Newton, Neerav Monga
European Respiratory Journal Sep 2016, 48 (suppl 60) PA3910; DOI: 10.1183/13993003.congress-2016.PA3910

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone
Francois Sincholle, Martin Kolb, Helene Manganas, Rabea El Keeb, Marc Newton, Neerav Monga
European Respiratory Journal Sep 2016, 48 (suppl 60) PA3910; DOI: 10.1183/13993003.congress-2016.PA3910
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Acute hyperoxic challenge improves haemodynamics & Pulmonary vascular stiffness in interstitial lung disease-associated pulmonary hypertension
  • Usual interstitial pneumonia preceding rheumatoid arthritis: Clinical, imaging, and histopathologic features
  • Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis
Show more 1.5 Diffuse Parenchymal Lung Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society